Bausch Health Companies Inc T.BHC

Alternate Symbol(s): BHC

Healthcare

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

TSX:BHC - Post by User

Bausch Health Companies Inc

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jul 31, 2024 12:42pm

149 Views

Post# 36156467

Earnings Report 📑🧐

i would not touch this with a 10 foot pole.

Bausch Health Companies (NYSE:BHC) is scheduled to announce Q2 earnings results on Thursday, August 1st, before market open.
The consensus EPS Estimate is $0.88 and the consensus Revenue Estimate is $2.34B (+7.8% Y/Y).
Over the last 2 years, BHC has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward. Revenue estimates have seen 2 upward revisions and 2 downward.
Recent earnings Analysis from our contributors:2 Red Alerts On Bausch Health Companies